Association between diabetes and oncological outcomes in patients undergoing neoadjuvant chemo-radiotherapy for rectal cancer

Fransgaard, Tina; Hallas, Jesper; Thygesen, Lau Caspar; Gögenur, Ismail

doi:10.1016/j.suronc.2018.11.007

Cited by 6 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of type 2 diabetes mellitus (T2DM) has been on the rise in recent years. Studies have confirmed that T2DM is significantly positively correlated with the occurrence and development of liver cancer, kidney cancer, colorectal cancer, and pancreatic cancer, among others (5,6). T2DM and TC are both diseases of the endocrine system.…”

Section: Original Articlementioning

confidence: 84%

“…T2DM is a common endocrine disease, and studies in recent years have suggested that T2DM is significantly correlated with the occurrence of TC (6,17) According to current studies (6,10), abnormal glucose metabolism caused by T2DM may be the main reason for its influence on the occurrence and development of TC. In this study, the differences in age and proportion of stage Ⅰ disease between patients with PTC combined with T2DM and patients with PTC alone were similar to those in previous studies (18).…”

Section: Discussionmentioning

confidence: 97%

“…Study showed that for PTC patients 44 years of age or younger, the increase in the prevalence of diabetes was more than twice expected (9). Currently, it is believed that T2DM's influence on malignant tumors is multi-dimensional, and the related causes of malignant tumors include oxidative stress injury, aggregation of various inflammatory factors, increase of tumor necrosis factor α, hyperglycemia and insulin resistance, among others (6,10). Hyperglycemia may be the primary risk factor.…”

Section: Original Articlementioning

confidence: 99%

See 2 more Smart Citations

Clinicopathological features and prognosis of papillary thyroid cancer patients with type 2 diabetes mellitus

Shi¹,

Zhang²,

Liu³

et al. 2022

Gland Surg

View full text Add to dashboard Cite

Background: The clinicopathological characteristics of patients with papillary thyroid carcinoma (PTC) combined with type 2 diabetes mellitus (T2DM) and patients with PTC alone were explored and compared in order to provide a more reasonable treatment plan for the clinical diagnosis and treatment of these patients.Methods: A total of 1,771 patients from January 2017 to December 2019 who underwent PTC surgery for the first time in the west branch of the Fourth Hospital of Hebei Medical University were analyzed retrospectively. Among them, 111 patients had PTC with T2DM (D-T group) and 1,660 patients had PTC alone (PTC group). The differences in general data and clinical characteristics between the D-T group and the PTC group were analyzed.Results: There were statistically significant differences in age, gender, and body mass index (BMI) between the D-T group and PTC group (P<0.05). Multifocality and extra-glandular invasion in the D-T group were significantly higher than the PTC group (P<0.05). In women, the D-T group was older, had a higher BMI, and was more likely to have extra-glandular invasion (P<0.05) than the PTC group. The prognosis of the D-T group was worse than that of the PTC group as determined by 3 well-developed prognostic staging systems, 8th AJCC TNM staging, MAGIS SCORE, AMES staging, and the results were statistically significant (P=0.001, P<0.001, P=0.021).Conclusions: Our study showed that the overall prognosis of PTC patients with T2DM was worse than that of patients with PTC alone. At the same time, especially in patients younger than 55 years of age, multifocal carcinoma and extra-glandular invasion are likely to occur. In addition, female patients with T2DM are more likely to have extra-glandular invasion than male patients. Therefore, for such patients, preoperative evaluation should be fully conducted.

show abstract

Section: Original Articlementioning

confidence: 84%

Section: Discussionmentioning

confidence: 97%

Section: Original Articlementioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological features and prognosis of papillary thyroid cancer patients with type 2 diabetes mellitus

Shi¹,

Zhang²,

Liu³

et al. 2022

Gland Surg

View full text Add to dashboard Cite

show abstract

“…Several epidemiological meta-analyses [ 7 , 8 , 25 , 26 ] and one additional study not included in the previously mentioned meta-analyses [ 27 ] have associated metformin use in patients with T2D and CRC with improved overall and disease-specific mortality. There has been an association in T2D patients who use metformin and who have undergone radical RC resection and subsequent chemoradiotherapy with either improved pathologic complete response and cancer-specific mortality [ 28 , 29 ] or no difference in the outcomes [ 30 , 31 ], when compared to metformin non-user patients with T2D. Our epidemiological study was one of the first to focus solely on RC in the general diabetic population, and we did not find convincing evidence about the association between metformin use, either pre-diagnostic or post-diagnostic, and reduced mortality from RC.…”

Section: Discussionmentioning

confidence: 99%

The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study

et al. 2022

View full text Add to dashboard Cite

Metformin and statin use have been associated with an improved prognosis for colorectal cancer in persons with type 2 diabetes (T2D). Data regarding rectal cancer (RC) have been inconclusive; therefore, we investigated the issue with high-quality data and a robust study design. We identified 1271 eligible patients with T2D and incident RC between 1998 and 2011 from the Diabetes in Finland (FinDM) database. Cox models were fitted for cause-specific mortality rates to obtain adjusted estimates of the hazard ratios (HR) with 95% confidence intervals (CI) in relation to use of antidiabetic medication (ADM) and statins before the RC diagnosis and for post-diagnostic use in a time-dependent exposure manner. No sufficient evidence was found for either pre- or post-diagnostic metformin use and RC mortality (HR 0.96, 95% CI 0.67–1.38, and 0.70, 95% CI 0.45–1.10, respectively) when compared to other oral ADMs. Both pre- and post-diagnostic statin use appeared to be inversely associated with mortality from RC (HR 0.77 95% CI 0.63–0.94, and 0.57, 95% CI 0.42–0.78, respectively). Our study was inconclusive as to the association of metformin use with the prognosis of RC, but statin use was found to predict reduced mortality, both from RC and from other causes of death in persons with T2D.

show abstract

Is Metformin Associated With Improved Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer?

Planellas

Cornejo

Rodríguez-Hermosa

et al. 2021

Journal of Surgical Research

View full text Add to dashboard Cite

Association between diabetes and oncological outcomes in patients undergoing neoadjuvant chemo-radiotherapy for rectal cancer

Abstract: Association between diabetes and oncological outcomes in patients undergoing neoadjuvant chemo-radiotherapy for rectal cancer Running head: Diabetes, chemo-radiation and rectal cancer

Cited by 6 publications

References 38 publications

Clinicopathological features and prognosis of papillary thyroid cancer patients with type 2 diabetes mellitus

Clinicopathological features and prognosis of papillary thyroid cancer patients with type 2 diabetes mellitus

The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study

Is Metformin Associated With Improved Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer?

Contact Info

Product

Resources

About